Finally, a unique advantage to covalently modifying the mutant KRASG12C protein with an inhibitor is the potential to specifically target drug-modified KRAS epitopes with antibodies or cell therapies [31], precisely flagging KRAS-mutant tumour cells for immune-mediated destruction. The gene discussed is KRAS; the disease is neoplasm.